Rong Tang

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang, Gang Zeng, Hongxing Pan et al. · The Lancet Infectious Diseases · 2020 · 1.5K citations · Full text

Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial

Jingxin Li, Shipo Wu, Xiling Guo et al. · The Lancet Respiratory Medicine · 2022 · 164 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +8

Associations of prenatal exposure to phenols with birth outcomes

Rong Tang, Minjian Chen, Guodong Ding et al. · Environmental Pollution · 2013 · 126 citations

Early Life Exposure, Gynecology, Maternal Health +5

Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial

Jingxin Li, Lihua Hou, Fanyue Meng et al. · The Lancet Global Health · 2016 · 101 citations · Full text

Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial

Yanjun Zhang, Gang Zeng, Hongxing Pan et al. · 2020 · 95 citations · Full text

Placebo-controlled Phase 2, Immunology, Vaccine Hesitancy +18